Loading...
Loading...
VRDN| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.3M |
| Operating Expense | 71.5M |
| Operating I/L | -71.5M |
| Other Income/Expense | 4.6M |
| Interest Income | 5.5M |
| Pretax | -66.9M |
| Income Tax Expense | 5.5M |
| Net Income/Loss | -66.9M |
Viridian Therapeutics, Inc. is a biotechnology company specializing in the development of treatments for serious diseases. Their product portfolio includes VRDN-001, a humanized monoclonal anti-IGF-1R antibody in Phase 1/2 clinical trial for thyroid eye disease (TED); VRDN-002, an IGF-1R antibody in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for TED treatment.
